Document:

<PAGE>
                                                                    Exhibit 4.2

Adopted by directors on March 28, 2003
Approved by shareholders on June 10, 2003

                       ANTIGENICS INC. DIRECTORS' DEFERRED
                                COMPENSATION PLAN

                                   ARTICLE I

                                    GENERAL

     1.1  Establishment of Plan. Antigenics Inc. ("Antigenics") hereby
establishes the Antigenics Directors' Deferred Compensation Plan (the "plan"),
effective as of June 11, 2003, to allow each member of the Antigenics Board of
Directors who is not also an officer or employee of Antigenics to defer receipt
of all or a portion of the cash compensation payable to him or her as a director
of Antigenics until his or her termination of service as a director or, subject
to requirements set forth in Section 3.1, such other date as may be specified by
him or her.

     1.2  No Right to Corporate Assets. This plan is unfunded and Antigenics
will not be required to set aside, segregate, or deposit any funds or assets of
any kind to meet its obligations hereunder. Nothing in this plan will give a
participant, a participant's beneficiary or any other person any equity or other
interest in the assets of Antigenics, or create a trust of any kind or a
fiduciary relationship of any kind between Antigenics and any such person. Any
rights that a participant, beneficiary or other person may have under this plan
will be solely those of a general unsecured creditor of Antigenics.

     1.3  Limitation on Rights Created by Plan. Nothing in this plan will give a
participant any right to continue as a director of Antigenics.

     1.4  Nonalienation of Benefits. The rights and benefits of a participant in
this plan are personal to the participant. No interest, right or claim under
this plan and no distribution therefrom will be assignable, transferable or
subject to sale, mortgage, pledge, hypothecation, anticipation, garnishment,
attachment, execution or levy, except by designation of beneficiaries as
provided in Section 3.6.

     1.5  Binding Effect of Plan. This plan will be binding upon and inure to
the benefit of participants and designated beneficiaries and their heirs,
executors and administrators, and to the benefit of Antigenics and its assigns
and successors in interest.

     1.6  Administration. This plan will be administered by the Chief Financial
Officer of Antigenics or other officer designated by the Board of Directors (the
"Administrator") who will have sole responsibility for its interpretation.

     1.7  Interpretation. This plan will be construed, enforced and administered
according to the laws of the Commonwealth of Massachusetts.

<PAGE>

                                   ARTICLE II

                            DEFERRAL OF COMPENSATION

     2.1  Deferral Agreement. Any member of the Board of Directors of Antigenics
who is not an officer or employee of Antigenics or its subsidiaries (an "outside
director") is eligible to participate in this plan. An outside director may
participate in the plan by executing an agreement before September 30 of any
year prior to the calendar year in which such agreement will take effect
authorizing Antigenics to defer all or a portion of his or her compensation as
director (the "deferral agreement"). A deferral agreement will remain in effect
for each succeeding calendar year unless the participant files a written
revocation or superseding deferral agreement with the Administrator. A deferral
agreement for any particular year is irrevocable after the last day of the
immediately preceding calendar year.

     2.2  Amount of Deferral. Each participant may elect in his or her deferral
agreement to defer 25 percent, 50 percent, 75 percent or 100 percent of the
total cash compensation paid to the participant as an outside director of
Antigenics.

     2.3  Deferral Account. For bookkeeping purposes only, the Administrator
will establish and maintain an account (the "deferral account") for each
participant which documents the compensation deferred by the participant,
earnings credited to the account and payments from the account. The deferral
account will consist of a subaccount for amounts earning interest, which will be
denominated on a dollar basis (the "cash account"), and a subaccount for amounts
invested in hypothetical shares of Antigenics common stock, $0.01 par value,
which will be denominated on a share basis (the "stock account"). Each
participant will indicate in his or her deferral agreement the percentage of
future deferrals to be invested in the cash account and the stock account.
Amounts may not be transferred between the cash account and the stock account.

     2.4  Cash Account. As of the tenth business day of each calendar year, the
Administrator will credit to the participant's cash account an amount equal to
the amount of compensation otherwise payable to the participant in the preceding
calendar year which the participant has elected to defer and invest in the cash
account. As of the last day of each calendar year, the Administrator will credit
interest on the balance in the cash account on that date at the rate paid on
one-year Treasury bills hypothetically purchased on the first day of such
calendar year. For a participant receiving installment payments, interest will
be credited on the balance from time to time remaining in the cash account until
the account has been completely paid.

     2.5  Stock Account. As of the tenth business day of each calendar year, the
Administrator will credit to the participant's stock account a number of units
representing shares of common stock equal to the amount of compensation
otherwise payable to the participant in the preceding calendar year which the
participant has elected to defer and invest in common stock divided by the
applicable stock price for such common stock. The applicable stock price shall
mean the average of the closing price for such common stock for all trading days
during the applicable calendar year as reported by the Nasdaq National Market
or, if not then traded on the Nasdaq National Market, as reported by a system or
organization selected by the Administrator. As of the date of payment of any
cash dividend on shares of common stock, the Administrator

                                       2

<PAGE>

will credit to the stock account a number of units representing shares of the
common stock equal to (i) the cash dividend per share times the number of units
representing shares credited to the stock account as of the dividend record date
divided by (ii) the closing price for such shares of common stock on the date of
payment of the dividend. As of the date of payment of any stock dividend on
shares of common stock, the Administrator will credit to the stock account a
number of units representing shares equal to the stock dividend declared times
the number of units representing shares of common stock upon which such dividend
was declared credited to the stock account as of the dividend record date. In
the event of any stock dividend, recapitalization, reorganization, merger,
consolidation, split-up, spin-off, exchange of shares or similar change
affecting the common stock, appropriate adjustment will be made in the number
and/or kind of units representing shares credited to the stock account. The
stock account is maintained for bookkeeping purposes only. Prior to distribution
to a participant under Section 3.3 or 3.4, units representing shares credited to
the stock account are not considered actual shares of common stock of Antigenics
for any purpose and a participant will have no rights as a stockholder with
respect to such shares. Units representing shares will include fractional units
computed to three decimal places.

     2.6  Shares Subject to the Plan. The aggregate number of shares of common
stock which have been reserved for issuance under this plan is 100,000. In the
event of any stock dividend, split-up, combination or reclassification of
shares, recapitalization or similar capital change relating to the common stock,
the maximum aggregate number and kind of shares or securities of Antigenics that
may be issued under the plan shall be appropriately adjusted by the Antigenics
Board of Directors (whose determination shall be conclusive).

                                  ARTICLE III

                        PAYMENT OF DEFERRED COMPENSATION

     3.1  Commencement of Payment. Each participant will elect in his or her
deferral agreement to have payments commence in the calendar year following his
or her termination of service as a director or such other calendar year as may
be specified; provided, however, that if a participant elects to have payments
commence in a calendar year other than the calendar year following his or her
termination of service as a director, the earliest calendar year that a
participant may elect to have payments commence shall be the second calendar
year following the date of such election. For example, a deferral agreement
executed in 2004 may not specify a payment commencement date earlier than 2006.
Such election will be irrevocable.

     3.2  Election of Form of Payment. Each participant will elect in his or her
deferral agreement to have his or her deferral account paid in either a lump sum
or in annual installments for a period specified by the participant, which
period may not exceed five years.

     3.3  Lump Sum Payments. A participant who elects to have his or her
deferral account paid in a lump sum will receive the lump sum payment on or
before March 1 of the year specified in the deferral agreement for commencement
of payment. The lump sum payment will consist of (a) cash in the amount credited
to his or her cash account, and (b) subject to Section 3.5, the number of shares
of common stock equal to the number of units representing shares credited to his
or her stock account; provided, however, that no fractional shares will be

                                       3

<PAGE>

issued under the plan and the number of shares issued will be rounded down to
the nearest full share.

     3.4  Installment Payments. A participant who elects to have his or her
deferral account paid in annual installments will receive an installment payment
on or before March 1 of each year that installments are due commencing with the
year specified in his or her deferral agreement. Each installment payment will
consist of (a) cash in the amount credited to his or her cash account on the
date of payment divided by the number of annual installments remaining to be
paid, and (b) subject to Section 3.5, the number of shares of common stock equal
to the number of units representing shares credited to his or her stock account
divided by the number of annual installments remaining to be paid; provided,
however, that no fractional shares will be issued under the plan and the number
of units representing shares issued will be rounded down to the nearest full
share.

     3.5  Limitation on Stock Distributions. If a participant would receive any
payment from his or her stock account in excess of the number of shares
remaining under the plan, such participant shall receive cash in an amount equal
to a number of units representing shares of common stock in his or her stock
account times the closing price for such common stock as of the trading day
preceding the date of distribution as is necessary to avoid exceeding such
remaining number. If more than one participant is in that situation, the
Administrator will determine allocations among participants.

     3.6  Beneficiaries. A participant may designate in his or her deferral
agreement a beneficiary or beneficiaries (which may be an entity other than a
natural person) to receive any payments to be made upon his or her death. A
participant may elect to have payments to beneficiaries paid in a lump sum or in
annual installments for a period not to exceed five years. At any time, and from
time to time, a participant may change or revoke his or her designation of
beneficiary or form of payment without the consent of any beneficiary. Any such
designation, change or revocation must be made in writing and filed with the
Administrator. If the participant designates more than one beneficiary, any
payments to beneficiaries will be made in equal percentages unless the
participant designates otherwise. Any portion of a participant's deferral
account that is not disposed of by designation of beneficiary upon the
participant's death will be paid to his or her estate.

     3.7  Payments on Death. If a participant dies before full payment of his or
her deferral account, Antigenics will make payments to the participant's
designated beneficiary or beneficiaries, or to his or her estate, of the amount
remaining in the deceased participant's deferral account. Such payments will be
in the form designated by the participant and will commence on the tenth
business day of the calendar year following the death of the participant (or as
soon thereafter as practicable) and, in the case of annual installments, will be
paid on or before March 1 of each succeeding year. The Administrator may, in his
or her discretion, accelerate payment of the cash account, but not the stock
account, upon a participant's death.

     3.8  Hardship Distributions from Accounts. The Administrator may, in his or
her discretion, distribute a portion or all of a participant's cash account in
case of an unanticipated emergency that is caused by an event beyond the control
of the participant and that would result in severe financial hardship to the
individual if early withdrawal were not permitted. The

                                       4

<PAGE>

Administrator will determine the date of payment of the distribution. Hardship
distributions are not permitted from a participant's stock account.

                                   ARTICLE IV

                            AMENDMENT AND TERMINATION

     4.1  Amendment. Antigenics may, without the consent of any participant,
beneficiary or other person, amend the plan at any time and from time to time;
provided, however, that no amendment will reduce the amount credited prior to
such amendment to the deferral account of any participant.

     4.2  Termination. Antigenics may terminate the plan at any time. Upon
termination of the plan, payments from a participant's deferral account shall be
made in the manner and at the time prescribed in Article III; provided, however,
that Antigenics may, in its discretion, distribute a participant's deferral
account in a lump sum as soon as practicable after the date the plan is
terminated.

                                       5

<PAGE>

                       ANTIGENICS INC. DIRECTORS' DEFERRED
                                COMPENSATION PLAN

                               DEFERRAL AGREEMENT

The undersigned, an outside director of Antigenics Inc. eligible to participate
in the Antigenics Inc. Directors' Deferred Compensation Plan (the "Plan"),
hereby elects as follows with respect to any director fees hereafter earned by
the undersigned, subject to the acknowledgment and agreement of the Plan's
Administrator:

PART I - DEFERRAL ELECTION

I elect to defer:

     ___________% of all amounts that would otherwise be cash compensation
     payments, or

     $__________ (but not more than 100% of such payments)

PART II - NOTIONAL INVESTMENT OF DEFERRALS

Allocate all amounts deferred hereunder as follows [ALLOCATIONS MUST TOTAL
100%]:

     Percentage allocated to the "cash account" as that term is
     defined in the Plan (not more than 100%):                     ________%

     Percentage allocated to the "stock account" as that term is
     defined in the Plan (not more than 100% minus the percentage
     allocated to cash account):                                   ________%

PART III - DISTRIBUTION

All amounts deferred hereunder will be paid (or commence to be paid) in [SELECT
ONE]:

     ______ The calendar year following the calendar year in which the
            undersigned ceases to serve as a director of the Company; or

     ______ Calendar year ___________ (see Section 3.1 of the Plan)

All amounts deferred hereunder will be paid either:

     _____ In a single lump sum, or

     _____ In annual installments over _____ (not more than five) years

The undersigned acknowledges that he/she has received a copy of the Plan and
that the elections made by this Form are subject in all respects to the terms of
the Plan. Without limiting the foregoing, the undersigned acknowledges that
amounts deferred hereunder represent an unfunded and unsecured obligation of
Antigenics Inc.; that the undersigned's right to any such deferred amounts are
those of a general creditor and are nontransferable except at death; that
nothing herein or in the Plan obligates Antigenics Inc. to establish a trust or
otherwise to set aside any assets to satisfy its obligations hereunder; and that
neither the elections set forth herein nor the beneficiary designation (if any)
set forth below shall

<PAGE>

take effect unless accepted the Administrator (as that term is defined in the
Plan). The undersigned hereby further acknowledges that the deferral election
set forth above applies only to fees earned after the date hereof and will
continue to apply for all future periods unless revoked or modified prior to the
beginning of the calendar year in which such revocation or modification is to
take effect.

                                              ______________________________
                                              Signature

Date:    _____________

BENEFICIARY DESIGNATION (OPTIONAL)

The above participant in the Plan, revoking any and all prior beneficiary
designations under the Plan, hereby designates the following person or persons
as beneficiary(ies) to receive any and all amounts (whenever deferred) that are
payable to the undersigned under the Plan and that remain unpaid at the death of
the undersigned:

Name: _________________________________

Address: ______________________________

         ______________________________

                                              ______________________________
                                              Signature

Date: _______________________

                          * * * * * * * * * * * * * * *

The foregoing Plan elections (and beneficiary designation, if any) are hereby
accepted and agreed:

                                              _______________________________
                                              Administrator

Date: _______________________<PAGE>
                                                                     Exhibit 4.1

                 SIXTH AMENDMENT TO CREDIT AGREEMENT AND WAIVER

     THIS SIXTH AMENDMENT TO CREDIT AGREEMENT AND WAIVER (this "Amendment"),
dated as of May 27, 2003, is entered into among (1) ALPHA TECHNOLOGIES GROUP,
INC., a Delaware corporation (the "BORROWER"), (2) the Lenders party to the
Credit Agreement referred to below and (3) UNION BANK OF CALIFORNIA, N.A., as
administrative agent for the Lenders (in such capacity, the "AGENT").

                                    RECITALS

     A.   The Borrower, the Lenders and the Agent previously entered into that
certain Credit Agreement dated as of December 26, 2000, as amended by that
certain Amendment to Credit Agreement and Waiver dated as of January 28, 2002,
that certain Second Amendment to Credit Agreement and Waiver dated as of March
4, 2002, that certain Third Amendment to Credit Agreement and Waiver dated as of
July 24, 2002, that certain Fourth Amendment to Credit Agreement dated as of
September 27, 2002 and that certain Fifth Amendment to Credit Agreement and
Waiver dated as of February 6, 2003 (as amended, the "CREDIT AGREEMENT").
Capitalized terms used herein and not defined shall have the meanings assigned
to them in the Credit Agreement.

     B.   The Borrower has informed the Agent and the Lenders that it is in
default of the Maximum Leverage Ratio covenant contained in Section 6.1(a) and
the Fixed Charge Coverage Ratio covenant contained in Section 6.1(b) of the
Credit Agreement for its Second Quarter End 2003.

     C.   In connection therewith, the Borrower has requested that the Lenders
(i) waive such Events of Default and (ii) modify the Maximum Leverage Ratio and
Fixed Charge Coverage Ratio covenants for Second Quarter End 2003, as more fully
set forth herein. The Lenders have agreed to grant such waiver and make such
changes, in each case subject to the terms and conditions set forth herein .

     D.   As of the date hereof, prior to the effectiveness of this Amendment,
(i) the aggregate principal amount of Revolving Loans outstanding under the
Credit Agreement is $3,200,000 and (ii) the aggregate principal amount of Term
Loans outstanding under the Credit Agreement is $20,150,000. The Aggregate
Revolving Loan Commitment is $5,000,000. There are no Letters of Credit
outstanding.

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
herein contained, the parties hereto hereby agree as follows:

     SECTION 1. AMENDMENTS TO CREDIT AGREEMENT. The Credit Agreement is hereby
amended as follows effective as of the date first set forth above, subject to
satisfaction of the conditions precedent set forth in Section 3 below:

<PAGE>

     (a) Section 6.1(a) of the Credit Agreement is restated in its entirety to
read as follows:

     "(a) MAXIMUM LEVERAGE RATIO. Permit the Maximum Leverage Ratio, as of the
end of any fiscal quarter of the Borrower, to exceed the following levels for
the periods indicated:

          Period                                      Ratio
          ------                                      -----

          Third Quarter End 2002                     5.00:1

          Fiscal Year End 2002                       4.45:1

          First Quarter End 2003                     4.70:1

          Second Quarter End 2003                    5.50:1

          Third Quarter End 2003                     4.90:1

          Fiscal Year End 2003                       4.50:1

          First Quarter End 2004 through and         1.85:1
          including Fiscal Year End 2004

          First Quarter End 2005 and thereafter      1.75:1

; PROVIDED, that for purposes of calculating the covenant in this Section 6.1(a)
only, the definition of "EBITDA" shall be deemed to read as follows:

          "EBITDA": for the Borrower and its Subsidiaries on a consolidated
     basis, for the fiscal quarter most recently ended and the immediately
     preceding three fiscal quarters, Net Income after eliminating extraordinary
     gains and losses, plus, without duplication, (i) provisions for income
     taxes, (ii) depreciation and amortization, (iii) Interest Expense, (iv)
     loan fees paid in connection with the Loan Documents (including (x) the
     effect, if any, of execution of warrant agreements in connection with the
     Loan Documents and (y) the amendment and waiver fee paid pursuant to the
     Third Amendment, the amendment fee paid pursuant to Section 3 of the Fourth
     Amendment, the amendment and waiver fee paid pursuant to Section 3 of the
     Fifth Amendment and the amendment fee paid pursuant to Section 3 of the
     Sixth Amendment), (v) $250,000 in Restructuring Charges for Fiscal Year
     2002, (vi) the amount of any annual impairment charges taken by the
     Borrower in connection with FAS Rule 142 and (vii) consultant fees paid in
     connection with Tactical Solutions, LLC's review of the Borrower."

     (b) Section 6.1(b) of the Credit Agreement is restated in its entirety to
     read as follows:

                                      -2-
<PAGE>

     "(b) FIXED CHARGE COVERAGE RATIO. Permit the Fixed Charge Coverage Ratio,
as of the end of any fiscal quarter of the Borrower, to be less than the
following levels for the periods indicated:

          Period                                   Ratio
          ------                                   -----

          Third Quarter End 2002                  1.15:1

          Fiscal Year End 2002                    1.00:1

          Second Quarter End 2003                 0.52:1

          Third Quarter End 2003                  1.10:1

          Fiscal Year End 2003                    1.15:1

          First Quarter End 2004 through and      0.80:1
          including Fiscal Year End 2004

          First Quarter End 2005 and thereafter   0.85:1

; PROVIDED, that for purposes of calculating the covenant in this Section 6.1(b)
only,

(i)  the Fixed Charge Coverage Ratio for Fiscal Year End 2002 shall be based on
the fiscal quarter most recently ended and the immediately preceding two fiscal
quarters only, without reference to any other fiscal quarter, and the Fixed
Charge Coverage Ratio for each of Second Quarter End 2003, Third Quarter End
2003 and Fiscal Year End 2003 shall be based on such respective fiscal quarter
only, without reference to any other fiscal quarter; and

(ii) the definition of "EBITDA" shall be deemed to read as follows:

          "EBITDA": for the Borrower and its Subsidiaries on a consolidated
     basis, for the fiscal quarter most recently ended and the immediately
     preceding three fiscal quarters, Net Income after eliminating extraordinary
     gains and losses, PLUS, without duplication, (i) provisions for income
     taxes, (ii) depreciation and amortization, (iii) Interest Expense, (iv)
     loan fees paid in connection with the Loan Documents (including (x) the
     effect, if any, of execution of warrant agreements in connection with the
     Loan Documents and (y) the amendment and waiver fee paid pursuant to the
     Third Amendment, the amendment fee paid pursuant to Section 3 of the Fourth
     Amendment, the amendment and waiver fee paid pursuant to Section 3 of the
     Fifth Amendment and the amendment fee paid pursuant to Section 3 of the
     Sixth Amendment), (v) $250,000 in Restructuring Charges for Fiscal Year
     2002, (vi) the amount of any annual impairment charges taken by the
     Borrower in connection with FAS Rule 142 and (vii) consultant fees paid in
     connection with Tactical Solutions, LLC's review of the Borrower."

                                      -3-
<PAGE>

     SECTION 2. WAIVERS.

     (a) Section 6.1(a) of the Credit Agreement requires that the Maximum
Leverage Ratio not exceed 4.95:1.00 for Second Quarter End 2003. The Borrower
has informed the Agent and the Lenders that its Maximum Leverage Ratio for such
period was 5.47:1.00. As a result of such noncompliance, an Event of Default has
occurred and is continuing under the Credit Agreement. At the Borrower's
request, the Lenders agree to waive such Event of Default, subject to the terms
and conditions set forth herein.

     (b) Section 6.1(b) of the Credit Agreement requires that the Fixed Charge
Coverage Ratio not be less than 0.95:1.00 for Second Quarter End 2003. The
Borrower has informed the Agent and the Lenders that its Fixed Charge Coverage
Ratio for such period was 0.54:1.00. As a result of such noncompliance, an Event
of Default has occurred and is continuing under the Credit Agreement. At the
Borrower's request, the Lenders agree to waive such Event of Default, subject to
the terms and conditions set forth herein.

     (c) The foregoing waivers are given in this instance only. The foregoing
waivers shall not be construed as a waiver of or consent to any violation of, or
deviation from, any other term or condition of the Credit Agreement or any other
Loan Document, nor shall such waivers be construed to evidence the willingness
of the Agent or the Lenders to give any other or additional waiver, whether in
similar or different circumstances.

     SECTION 3. CONDITIONS PRECEDENT. This Amendment shall become effective as
of the date first set forth above upon receipt by the Agent of the following:

     (a) this Amendment, duly executed by the Borrower and the Majority Lenders;

     (b) evidence of the Guarantors' consent to this Amendment, substantially in
the form of EXHIBIT A hereto;

     (c) evidence in form and substance satisfactory to the Agent that the
insurance policies provided for in Section 5.5 of the Credit Agreement
(including keyman insurance) are in full force and effect, together with
appropriate evidence showing the Agent as an additional named insured or loss
payee, as appropriate, for the benefit of the Lenders;

     (d) an amendment fee equal to fifteen basis points on the sum of the
outstanding Term Loans and the Aggregate Revolving Commitment, which is $37,725,
in immediately available funds, to be shared pro rata by the Lenders executing
this Amendment on or before May 27, 2003, and all outstanding fees and expenses
of the Agent including legal fees incurred in connection with the negotiation,
drafting and execution of this Amendment to the extent requested by the Agent to
be paid in connection herewith; and

     (e) such other documents, agreements and opinions as the Agent or any
Lender may request.

     SECTION 4. REFERENCE TO AND EFFECT ON THE CREDIT AGREEMENT AND THE OTHER
LOAN DOCUMENTS.(a) Upon the effectiveness of this Amendment, each reference in
the Credit Agreement to "this Agreement," "hereunder," "hereof" or words of like
import referring to the Credit

                                      -4-
<PAGE>

Agreement, and each reference in the other Loan Documents to "the Credit
Agreement," "thereunder," "thereof" or words of like import referring to the
Credit Agreement, shall mean and be a reference to the Credit Agreement, as
amended hereby.

     (b) Except as specifically amended herein, the Credit Agreement and all
other Loan Documents are and shall continue to be in full force and effect and
are hereby in all respects ratified and confirmed.

     (c) The execution, delivery and effectiveness of this Amendment shall not
operate as a waiver of any right, power or remedy of the Agent or the Lenders
under the Credit Agreement or any other Loan Documents, nor constitute a waiver
of any provision of the Credit Agreement or any other Loan Documents, except as
specifically set forth herein.

     SECTION 5. REPRESENTATIONS AND WARRANTIES. The Borrower hereby represents
and warrants, for the benefit of the Lenders and the Agent, as follows: (i) the
Borrower has all requisite power and authority under applicable law and under
its charter documents to execute, deliver and perform this Amendment, and to
perform the Credit Agreement as amended hereby; (ii) all actions, waivers and
consents (corporate, regulatory and otherwise) necessary or appropriate for the
Borrower to execute, deliver and perform this Amendment, and to perform the
Credit Agreement as amended hereby, have been taken and/or received; (iii) this
Amendment, and the Credit Agreement, as amended by this Amendment, constitute
the legal, valid and binding obligation of the Borrower enforceable against it
in accordance with the terms hereof; (iv) the execution, delivery and
performance of this Amendment, and the performance of the Credit Agreement, as
amended hereby, will not (a) violate or contravene any material Requirement of
Law, (b) result in any material breach or violation of, or constitute a material
default under, any agreement or instrument by which the Borrower or any of its
property may be bound, or (c) result in or require the creation of any Lien upon
or with respect to any properties of the Borrower, whether such properties are
now owned or hereafter acquired; (v) the representations and warranties
contained in the Credit Agreement and the other Loan Documents are correct in
all material respects on and as of the date of this Amendment, after giving
effect to the same, as though made on and as of such date; and (vi) except as
discussed in Section 2 of this Amendment, no Default has occurred and is
continuing.

     SECTION 6. EXECUTION IN COUNTERPARTS. This Amendment may be executed in any
number of counterparts and by different parties hereto in separate counterparts,
each of which when so executed and delivered shall be deemed to be an original
and all of which taken together shall constitute but one and the same agreement.
Delivery of an executed counterpart of a signature page to this Amendment by
telecopier shall be effective as delivery of a manually executed counterpart of
this Amendment.

     SECTION 7. GOVERNING LAW. THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF
THE PARTIES UNDER THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND
INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF CALIFORNIA (WITHOUT
REFERENCE TO ITS CHOICE OF LAW RULES).

                                      -5-
<PAGE>

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]

                                      -6-
<PAGE>

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
duly executed and delivered by their proper and duly authorized officers as of
the day and year first above written.

                                        ALPHA TECHNOLOGIES GROUP, INC.

                                        By: /s/ Lawrence Butler
                                        Name: Lawrence Butler
                                        Title: Chairman and Chief Executive
                                               Officer

                                        UNION BANK OF CALIFORNIA, N.A., as Agent
                                          and as a Lender

                                        By: /s/ Cecilia M. Valente
                                        Name: Cecilia M. Valente
                                        Title: Senior Vice President

                                        CALIFORNIA BANK & TRUST, as a Lender

                                        By: /s/ Robert K. Chaulk
                                        Name: Robert K. Chaulk
                                        Title: Senior Vice President

                                        IBM CREDIT LLC, as a Lender

                                        By: /s/ Steven A. Flanagan
                                        Name: Steven A. Flanagan
                                        Title:  Manager, Global Special Handling

                                        MANUFACTURERS BANK
                                        A California Banking Corporation,
                                          as a Lender

                                        By: /s/ Karen J. Kearney
                                        Name: Karen J. Kearney
                                        Title: Vice President

                                      S-1
<PAGE>

                                        U.S. BANK NATIONAL ASSOCIATION,
                                        as a Lender

                                        By: /s/ E. C. Hengeveld
                                        Name: Elizabeth C. Hengeveld
                                        Title: Vice President

                                      S-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]